Overview of JPMorgan's Rating#
JPMorgan has started coverage on First Tracks Biotherapeutics (NASDAQ:TRAX) with an Overweight rating, indicating that they believe the stock has strong growth potential. The firm has set a price target of $31.00, while the stock is currently trading at $18.87. This suggests that there could be significant room for growth.
Company Background#
First Tracks Biotherapeutics is a clinical-stage company focused on immunology, which is the study of the immune system. The company was previously known as BioPharma Co before separating from AnaptysBio. Its leading drug candidate, ANB033, is being tested for treating Celiac Disease and Eosinophilic Esophagitis, both of which are conditions that affect the digestive system.
Upcoming Data and Pipeline#
The company is expecting important data from its clinical trials soon. Phase 1b results for ANB033 in Celiac Disease are anticipated in the fourth quarter of 2026, while results for Eosinophilic Esophagitis are expected in mid-2027. Additionally, First Tracks is developing another drug, rosnilimab, for Rheumatoid Arthritis, which relies on partnerships and external funding. An update on this drug is expected in the second quarter of 2026.
Analyst Attention and Market Potential#
Recently, First Tracks Biotherapeutics has garnered attention from other financial firms as well. Barclays has also rated the company as Overweight with a price target of $40.00, while UBS has assigned a buy rating with a target of $45.00. UBS emphasized the potential of ANB033, noting that the conditions it targets could lead to over $3 billion in peak sales. Both Barclays and UBS see significant promise in the company’s pipeline, which includes various treatments for inflammatory diseases, indicating a growing interest in First Tracks Biotherapeutics' future prospects.